Okyo Pharma Limited ADR (OKYO) Stock Price, Quote & News

Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acu...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: okyopharma.com

Address:

14/15 Conduit St, Floor 4, London, United Kingdom

Orlandotrader Mar. 19 at 2:32 PM

$OKYO John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company’s ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares.

0 · Reply

DARKP00L Mar. 19 at 2:23 PM

$OKYO 10:06 on Mar. 19 2026 OKYO Pharma Director John Brancaccio Buys 5,000 Shares At An Average Price Of $1.61, Raising Total Holdings to 31,201 #tradeideas

0 · Reply

DARKP00L Mar. 19 at 11:20 AM

$OKYO 07:13 on Mar. 19 2026 OKYO Pharma Executive Buys More Shares, Signals Confidence #tradeideas

0 · Reply

BioTuesdays Mar. 18 at 4:33 PM

$OKYO has announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod for the treatment of neuropathic corneal pain (NCP). https://biotuesdays.com/2026/03/18/okyo-reports-new-phase-2-data-for-urcosimod-in-ncp/

0 · Reply

DARKP00L Mar. 18 at 11:20 AM

$OKYO 07:10 on Mar. 18 2026 OKYO Pharma Reports Trial Results For Eye Pain Treatment #tradeideas

0 · Reply

MrTicker Mar. 18 at 11:14 AM

$OKYO OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain GLOBENEWSWIRE 6:00 AM ET 3/18/2026

0 · Reply

DARKP00L Mar. 18 at 11:11 AM

$OKYO 07:10 on Mar. 18 2026 OKYO Pharma Reports Trial Results For Eye Pain Treatment #tradeideas

0 · Reply

rp6577 Mar. 18 at 11:05 AM

$OKYO https://x.com/okyopharma/status/2034223289581908257?s=46&t=ca2qCrnqXP8cBaayMxMU6g $XBI

0 · Reply

OfficialStocktwitsUser Mar. 14 at 2:32 AM

$OKYO RSI: 45.45, MACD: -0.0842 Vol: 0.03, MA20: 1.71, MA50: 2.03 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Oscarca Mar. 11 at 8:55 AM

$OKYO Trials are starting in June so we can hope that news regarding enrollment will come out at any day 🙏🏼

0 · Reply

OKYO Pharma Announces Chairman and Founder Acquires Shares

Mar 19, 2026, 10:00 AM EDT - 2 days ago

OKYO Pharma Announces Director Acquires Shares

Mar 19, 2026, 7:00 AM EDT - 2 days ago

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

Mar 18, 2026, 7:00 AM EDT - 3 days ago

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

Feb 23, 2026, 11:00 AM EST - 26 days ago

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

Feb 12, 2026, 10:20 PM EST - 5 weeks ago

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

Feb 12, 2026, 4:01 PM EST - 5 weeks ago

OKYO Pharma Announces Public Offering of Ordinary Shares

Feb 11, 2026, 10:09 AM EST - 5 weeks ago

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

Feb 10, 2026, 8:00 AM EST - 5 weeks ago

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

Jan 30, 2026, 11:30 AM EST - 7 weeks ago

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

Jan 28, 2026, 7:40 AM EST - 7 weeks ago

OKYO Pharma Announces Successful Type C Meeting with the FDA

Jan 23, 2026, 7:00 AM EST - 2 months ago

FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

Dec 19, 2025, 7:00 AM EST - 3 months ago

OKYO Pharma to Ring the Opening Bell at Nasdaq

Nov 18, 2025, 8:30 AM EST - 4 months ago

OKYO Pharma to Present at OIS XV in San Diego

Sep 22, 2025, 8:30 AM EDT - 6 months ago

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

Jul 16, 2025, 9:21 AM EDT - 8 months ago

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Jun 11, 2025, 10:05 AM EDT - 10 months ago

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

May 19, 2025, 7:00 AM EDT - 10 months ago

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

Apr 30, 2025, 7:00 AM EDT - 11 months ago

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Mar 31, 2025, 8:00 AM EDT - 1 year ago

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Jan 31, 2025, 7:00 AM EST - 1 year ago

OKYO Pharma Announces Chairman and CEO Acquire Shares

Jan 30, 2025, 9:45 AM EST - 1 year ago

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

Nov 15, 2024, 9:00 AM EST - 1 year ago

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MUSQ

Oct 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SMXT

Aug 23, 2024, 9:00 AM EDT - 1 year ago

OKYO Pharma CEO Interview to Air on Bloomberg TV

Aug 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Chairman Acquires Shares

Aug 15, 2024, 12:13 PM EDT - 1 year ago

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 6, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

Jul 11, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Jul 10, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Apr 30, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

Apr 8, 2024, 7:00 PM EDT - 2 years ago

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

$OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery$

Apr 2, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Mar 22, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Mar 21, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Mar 20, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Feb 9, 2024, 7:00 AM EST - 2 years ago

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Jan 5, 2024, 9:30 AM EST - 2 years ago

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Oct 9, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

Sep 15, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 9:15 AM EDT - 2 years ago

OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

Sep 14, 2023, 8:45 AM EDT - 2 years ago

OKYO Pharma Limited Announces Withdrawal of Public Offering

Sep 8, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Aug 30, 2023, 7:00 AM EDT - 2 years ago

OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)

Aug 15, 2023, 9:00 AM EDT - 2 years ago

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

Jul 28, 2023, 5:25 PM EDT - 2 years ago

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

Jul 28, 2023, 5:05 PM EDT - 2 years ago

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

Jul 28, 2023, 7:01 AM EDT - 2 years ago

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

Jul 27, 2023, 11:30 AM EDT - 2 years ago

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

Orlandotrader Mar. 19 at 2:32 PM

$OKYO John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company’s ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares.

0 · Reply

DARKP00L Mar. 19 at 2:23 PM

$OKYO 10:06 on Mar. 19 2026 OKYO Pharma Director John Brancaccio Buys 5,000 Shares At An Average Price Of $1.61, Raising Total Holdings to 31,201 #tradeideas

0 · Reply

DARKP00L Mar. 19 at 11:20 AM

$OKYO 07:13 on Mar. 19 2026 OKYO Pharma Executive Buys More Shares, Signals Confidence #tradeideas

0 · Reply

BioTuesdays Mar. 18 at 4:33 PM

0 · Reply

DARKP00L Mar. 18 at 11:20 AM

$OKYO 07:10 on Mar. 18 2026 OKYO Pharma Reports Trial Results For Eye Pain Treatment #tradeideas

0 · Reply

MrTicker Mar. 18 at 11:14 AM

0 · Reply

DARKP00L Mar. 18 at 11:11 AM

$OKYO 07:10 on Mar. 18 2026 OKYO Pharma Reports Trial Results For Eye Pain Treatment #tradeideas

0 · Reply

rp6577 Mar. 18 at 11:05 AM

$OKYO https://x.com/okyopharma/status/2034223289581908257?s=46&t=ca2qCrnqXP8cBaayMxMU6g $XBI

0 · Reply

OfficialStocktwitsUser Mar. 14 at 2:32 AM

0 · Reply

Oscarca Mar. 11 at 8:55 AM

$OKYO Trials are starting in June so we can hope that news regarding enrollment will come out at any day 🙏🏼

0 · Reply

Br200270 Mar. 10 at 7:05 PM

$OKYO how we lookin?

3 · Reply

WilliamsEmpire Feb. 26 at 7:58 PM

$OKYO when is the next potential catalyst?

1 · Reply

Orlandotrader Feb. 23 at 5:23 PM

$OKYO OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, scheduled for May 3 to 7 in Denver, Colorado. Chief scientific officer Dr Raj Patil is set to present the findings from OKYO’s Phase 2a proof-of-concept clinical trial of urcosimod, a preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity for NCP. We are honored that our urcosimod data has been selected for presentation at ARVO 2026, one of the world’s leading forums for vision and ophthalmology research,” Patil said in a statement.

1 · Reply

Orlandotrader Feb. 22 at 6:32 PM

$OKYO The near-term catalyst is an ASCRS (American Society of Cataract and Refractive Surgery) presentation on April 11, with Phase 2b/3 initiation expected in H1 2026. A key de-risking event already occurred: FDA's Type C meeting in January 2026 endorsed the study design and CMC (chemistry, manufacturing, controls) strategy. Phase 2 data showed 75% of patients achieved greater than 80% pain reduction at the 0.05% dose. More importantly, December 2025 data demonstrated directional improvements in corneal nerve fiber count and length — mechanistic evidence of actual nerve regeneration, not just symptom masking. This nerve regeneration signal was absent in placebo patients. The micellar formulation enhances ocular surface delivery, and OKYO holds first-mover status in NCP clinical development.

0 · Reply

Oscarca Feb. 20 at 2:44 PM

$OKYO market is bad but let’s go

0 · Reply

rp6577 Feb. 20 at 2:41 PM

$OKYO part of me feels like they are tapping the ATM a bit everytime the share price pops it head over $1.80

0 · Reply

moosegoose Feb. 20 at 2:19 PM

$OKYO back in with a 1.75 avg. let’s head back to $3

0 · Reply

notreload_ai Feb. 20 at 11:11 AM

Piper Sandler starts coverage on $OKYO with an Overweight rating and $7 target. Analyst likes lead drug Urcosimod for eye pain with no current treatments – strong early results and good safety. https://notreload.xyz/okyo-pharma-coverage-overweight/

0 · Reply

erevnon Feb. 20 at 10:43 AM

Piper Sandler initiates coverage on OKYO Pharma $OKYO at Overweight rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

rp6577 Feb. 17 at 6:50 PM

$TLSA and $OKYO looking great right now. Both now well funded with plenty of cash in the bank. Tiziana with imminent phase 2 SPMS data and MSA to follow. Alzheimer’s data could arise by the year end. So many indications. Big markets and impeccable safety. Potential blockbuster. Okyo cracking on with a phase 2b/3 trial with results in Jan 2027, with fast track designation. Also with DED in the background as a great bolt on for big pharma. Can easily see a partnership arising later this year or just a straight buy out once data released. Great opportunity $XBI $LABU

0 · Reply

rp6577 Feb. 17 at 5:07 PM

$OKYO 🔥 great opportunity here

0 · Reply

dddanielek Feb. 17 at 2:24 AM

$OKYO now we know why they pumped this up with the help of Charlie so they can drop an offering at the higher price. Classic move.

0 · Reply

Market Cap	65.70M
Revenue (ttm)	0.00
Net Income (ttm)	-4.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.06

Volume	83,000
Avg Vol	301,028
Day's Range	N/A - N/A
Shares Out	40.56M
Stochastic %K	28%
Beta	-0.02
Analysts	Strong Sell
Price Target	$8.00